SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

26 Jul 2022 Evaluate
The topline stands at Rs. 35.39 millions for the June 2022 quarter. The mentioned figure indicates a rise of about 76.42% as against Rs. 20.06 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -23.13 millions as compared to Net Loss of Rs. -84.92 millions of corresponding quarter ended June 2021 Operating profit Margin for the quarter ended June 2022 improved to -66.30% as compared to -110.21% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 35.39 20.06 76.42 35.39 20.06 76.42 118.44 134.78 -12.12
Other Income 4.36 8.40 -48.10 4.36 8.40 -48.10 53.17 77.54 -31.43
PBIDT -66.30 -110.21 -39.84 -66.30 -110.21 -39.84 -313.26 -227.93 37.44
Interest 1.02 1.53 -33.33 1.02 1.53 -33.33 5.30 8.15 -34.97
PBDT -7.32 -74.58 -90.19 -7.32 -74.58 -90.19 -318.56 -236.08 34.94
Depreciation 15.81 10.34 52.90 15.81 10.34 52.90 43.93 43.46 1.08
PBT -23.13 -84.92 -72.76 -23.13 -84.92 -72.76 -362.49 -279.54 29.67
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -53.23 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -53.23 0.00
PAT -23.13 -84.92 -72.76 -23.13 -84.92 -72.76 -362.49 -226.31 60.17
Equity 145.38 127.28 14.22 145.38 127.28 14.22 145.38 127.28 14.22
PBIDTM(%) -187.34 -549.40 -65.90 -187.34 -549.40 -65.90 -264.49 -169.11 56.40

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×